Global Botulinum Toxin Market to Reach $7.9 Billion by 2026

Abstract: Global Botulinum Toxin Market to Reach $7. 9 Billion by 2026 . Botulinum toxin, a neurotoxin produced by Clostridium Botulinum bacterium, is capable of arresting release of acetylcholine, thus leading to muscle relaxation.

New York, July 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Botulinum Toxin Industry" - https://www.reportlinker.com/p0119494/?utm_source=GNW
Manufactured under controlled laboratory conditions and administered in extremely small therapeutic doses, BTX is administered intravenously only at the affected site. Growth in the global market is driven by growing demand in medical/therapeutic and cosmetic applications. The growing acceptance of facial injectables such as BTX to facial aesthetics among adults and approval for using therapeutic BTX in the treatment of an expanded range of indications is expected to spur market expansion. The constant development and launch of novel products for enhancing aesthetic appeal and the growing demand for minimally invasive treatments in cosmetology as well as therapeutic applications are boosting demand in the market. In the field of neuromuscular therapeutics, the use of botulinum toxin is driven by rising incidences of movement related disorders and growing number of patients with muscle spasms. Further, new clinical indications of botulinum toxin such as in the treatment of nystagmus, stridor, palatal myoclonus, scoliosis, co-spasms following brachial plexus lesions (birth related), and gait freezing (Parkinson), have helped further strengthen growth in this space.

Amid the COVID-19 crisis, the global market for Botulinum Toxin estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$7.9 Billion by 2026, growing at a CAGR of 8.2% over the analysis period. Type A, one of the segments analyzed in the report, is projected to record 8.2% CAGR and reach US$8.5 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Type B segment is readjusted to a revised 6.9% CAGR for the next 7-year period. Botulinum toxin type A finds use in the treatment of movement disorders, vocal cord dysfunction and obesity, and is also used as a medical aid in gastric cancer. Growth in the botulinum toxin type A will be driven by its increasing use in the treatment of muscle spasms in cerebral palsy as well as neurogenic bladder diseases occurring in children. Type B is used for various muscle related conditions. Botulinum neurotoxin type B was approved by the FDA in 2000 for treatment of for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain linked with cervical dystonia.

The U.S. Market is Estimated at $3.1 Billion in 2021, While China is Forecast to Reach $665 Million by 2026

The Botulinum Toxin market in the U.S. is estimated at US$3.1 Billion in the year 2021. China, the world`s second largest economy, is forecast to reach a projected market size of US$665 Million by the year 2026 trailing a CAGR of 14.8% over the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.1% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.1% CAGR. The United States represents the largest regional market, driven mainly by the growing approval for newer therapeutic indications. Further the increasing focus on improving physical appearance, rising disposable incomes of people, and the subsequent rise in demand for cosmetic procedures is also fueling growth. Rising demand for non-invasive or minimally invasive aesthetic treatments is also contributing to the growth of Botox market in the US. Europe also offers attractive opportunities for the botox market owing to the presence of a large number of cosmetic product manufacturers. Rapidly improving socio-economic conditions and proliferation of medical tourism, particularly in Asian countries, presents favorable prospects for botulinum toxin in Asia-Pacific region.
Select Competitors (Total 28 Featured)

• AbbVie

• Daewoong Pharmaceutical Co., Ltd.

• HUGEL Pharma

• Ipsen Group

• Medy-Tox Inc.

• Merz Pharma GmbH & Co. KGaA

• Metabiologics, Inc.

• Revance Therapeutics, Inc.

• US WorldMeds

Read the full report: https://www.reportlinker.com/p0119494/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
COVID-19 Disruptions Impact Botulinum Toxin Business
Virtual Care to the Fore amid COVID-19
Aesthetic Clinics to Follow Infection-Prevention Measures to
Mitigate Risk of COVID-19 Infection Transmission
EXHIBIT 1: % Rise in Migraine Attacks due to COVID-19 Pandemic
for March 2020
COVID-19 Disruptions Highlight Significance of Botulinum Toxin
Therapy for Associated Medical Conditions
Researchers Eye on Botulinum Toxin as Potential Therapeutic
Option to Alleviate and Manage COVID-19 Infection
Botulinum Toxin: An Introduction
Outlook
Therapeutic BTX Applications Lead
Cosmetic BTX Gradually Gains Momentum
Factors Propelling the Cosmetic BT Market: In a Nut Shell
EXHIBIT 2: Percent of Plastic Surgeons Performing Botulinum
Toxin Surgical Procedures in Select Countries: 2019
Developed Regions Dominate Botulinum Toxin Market
Developing Markets to Drive Future Growth
Competitive Landscape
Intense Competition Characterizes Botulinum Toxin Market
EXHIBIT 3: Market Share of Leading Players in Global Botulinum
Toxin Market: 2019
Select Approved Botulinum Toxin Products Worldwide
Companies Entering the Fray
Pharma Companies Eye Lucrative BT Market
Biosimilar BTX Variants Challenge Botox?s Leadership
Lack of Differentiation among Approved BTX Products
Comparison of Leading Neurotoxins - Botox, Dysport and Xeomin
by Safety and Efficacy
Comparison of Botox®, Dysport® and Xeomin® by Indications and
Year of Approval
BOTOX®
Approvals and Indications of Botox in Select Regions
Botox Therapeutic Approvals in the US by Indication
Ipsen Counts on New Indications for Future Growth of Dysport
Xeomin®
Merz
Other Products
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Rising Demand for Non-Invasive Cosmetic Treatments Bodes Well
for BTX Market
EXHIBIT 4: Non-Surgical Cosmetic Procedures Worldwide (2018):
Percentage Breakdown of Procedure Volumes
Botulinum Toxin: The Preferred Solution in Facial Injectables
Market
EXHIBIT 5: Cosmetic Botulinum Toxin Procedures Performed
Worldwide (2019): Percentage Breakdown of Procedure Volume by
Gender
Millennials: A Popular Demographic for Botulinum Toxin
EXHIBIT 6: Cosmetic Botulinum Toxin Procedures Performed
Worldwide (2019): Percentage Breakdown of Procedure Volume by
Age Group Age Group % Share
Therapeutic Areas and Opportunities
Botox Therapeutic Applications Uses and Indications
EXHIBIT 7: Global Therapeutic BTX Neurotoxin Market Breakdown
by Therapeutic Indication (2019)
Botulinum Toxin Remains Gold Standard for Treatment of Focal
Spasticity
Rise in the Number of Musculoskeletal Indications: Potential
for Growth
Unmet Medical Needs Encourage Off-Label Use: A Cause for
Concern or Jubilation?
Combination Therapies: A Double Whammy Success
Botulinum Toxin: Potential Applications in Treatment of Dental
Diseases
Potential Applications in Dentistry
Short-lived Aesthetic Effects: A Strong Business Case for
Revision Treatments
Novel Injection Systems for Highly Precise Dosage of Botulinum
Toxin
Longer Life Expectancy and Rising Disposable Incomes Propel
Sales of Cosmetic BTX
EXHIBIT 8: Life Expectancy at Birth in Years of People in
Select Countries
EXHIBIT 9: Life Expectancy at Birth (in Years) of Men and Women
by Region
Increase in Healthcare Spending Stirs Demand for BTX in
Therapeutic Applications
Current Health Expenditure (CHE) as Percentage Of Gross
Domestic Product (GDP) (%): 2017
EXHIBIT 10: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023
Challenges and Issues
Undesirable Side Effects: A Challenge to Reckon With
Immunogenicity Undermines Patient Compliance
Antigenicity: A Problematic Issue in Drug Development
Potential Adverse Side Effects: A Major Barrier to Success
Stringent Regulations Delay Market Approvals
Higher Product Costs to Challenge Market Growth
Consumer Skepticism: The Biggest Challenge to Beat
Animal Cruelty:A Part & Parcel of Botox Testing

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Botulinum Toxin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Botulinum Toxin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Botulinum Toxin by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Type A by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 5: World Historic Review for Type A by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America and Rest of World Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 6: World 15-Year Perspective for Type A by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Type B by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Type B by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America and Rest of World Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 9: World 15-Year Perspective for Type B by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Therapeutics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Therapeutics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America and Rest of World Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 12: World 15-Year Perspective for Therapeutics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Aesthetics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Aesthetics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America and Rest of World Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 15: World 15-Year Perspective for Aesthetics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Specialty &
Dermatology Clinics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Specialty & Dermatology
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Specialty & Dermatology
Clinics by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Hospitals &
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Hospitals & Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Hospitals & Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America
and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Market Overview
Opportunities in Store for Cosmetic BTX
EXHIBIT 11: Age-wise Distribution for Botulinum Toxin
Procedures Performed in the US for the Year 2019
EXHIBIT 12: Gender Distribution for Botulinum Toxin Procedures
Performed in the US (2019)
Increasing Demand for Cosmetic Treatments Bodes Well for BTX
Market
Cosmetic Procedures: Facts and Figures
EXHIBIT 13: Number of Surgical & Non-Surgical Cosmetic
Procedures (’000s) in the US for the Years 2000, 2018 & 2019
EXHIBIT 14: Top 5 Surgical Cosmetic Procedures in the US -
Ranked by the Number of Procedures Performed (In ?000s) for
2019
EXHIBIT 15: Top 4 Non-Surgical Cosmetic Procedures in the US -
Ranked by the Number of Procedures Performed (?000s) for 2019
EXHIBIT 16: Number of Botulinum Toxin Procedures* Performed in
the US: 2000, 2016 and 2019
Aging Baby Boomers Drive Aesthetic Business
EXHIBIT 17: US Population by Age Group (2017): Percentage
Breakdown for 0-14, 15-24, 25-59 and 65+ Age Groups
EXHIBIT 18: North American Aging Population by Age Group: 1975
-2050
Expanding Physician Base Extends Impetus to Growth
Therapeutic BTX Seeks Growth Opportunities
Approved Therapeutic Indications of Botulinum Toxin in the US
by Year of Approval
Neurogenic OAB: A Lucrative Market Opportunity
Competitive Landscape
Major BTX Products and Associated Fillers in the Cosmetic
Botulinum Toxin Market
EXHIBIT 19: Market Share of Leading Brands in the US Boulinum
Toxin Market: 2019
Dysport Poses Strong Competition to Botox in the Therapeutic Space
Table 25: USA Current & Future Analysis for Botulinum Toxin by
Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 26: USA Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 28: USA Current & Future Analysis for Botulinum Toxin by
Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 29: USA Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 30: USA 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Botulinum Toxin by
End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics
and Other End-Uses - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

CANADA
Table 34: Canada Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 35: Canada Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: Canada 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 37: Canada Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 38: Canada Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 39: Canada 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 41: Canada Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

JAPAN
Market Overview
EXHIBIT 20: Non-Surgical Aesthetic Procedures in Japan (2019):
Percentage Breakdown of Number of Procedures by Procedure Type
Procedure % Share
Table 43: Japan Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 44: Japan Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Japan 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 46: Japan Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 47: Japan Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 48: Japan 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 50: Japan Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

CHINA
Market Overview
Uptrend in Facial Injectables Market Favors Market Expansion
Regulatory Scenario
Approved Botulinum Toxin Injections in China
Competition
Market Share of Leading Players in Chinese Botulinum Toxin
Market: 2019
Table 52: China Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 53: China Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: China 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 55: China Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 56: China Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 57: China 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 58: China Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 59: China Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

EUROPE
Market Overview
Botox Approvals and Indications in Select European Countries
EXHIBIT 21: Non-Surgical Aesthetic Procedures in Select
European Countries (2019): Percentage Breakdown of Number of
Procedures by Procedure Type
Regulations for Botulinum Toxin Usage in the EU
Table 61: Europe Current & Future Analysis for Botulinum Toxin
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2020 through 2027 and %
CAGR

Table 62: Europe Historic Review for Botulinum Toxin by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: Europe 15-Year Perspective for Botulinum Toxin by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 64: Europe Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 65: Europe Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 68: Europe Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 69: Europe 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 71: Europe Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

FRANCE
Table 73: France Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 74: France Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: France 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 76: France Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 77: France Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 78: France 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 79: France Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 80: France Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

GERMANY
Table 82: Germany Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 83: Germany Historic Review for Botulinum Toxin by
Product - Type A and Type B Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 84: Germany 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 85: Germany Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 86: Germany Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 87: Germany 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 89: Germany Historic Review for Botulinum Toxin by
End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics
and Other End-Uses Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 90: Germany 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

ITALY
Table 91: Italy Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 92: Italy Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 93: Italy 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 94: Italy Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 95: Italy Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 96: Italy 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 97: Italy Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 98: Italy Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 99: Italy 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

UNITED KINGDOM
Market Overview
Snapshots
Table 100: UK Current & Future Analysis for Botulinum Toxin by
Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 101: UK Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 102: UK 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 103: UK Current & Future Analysis for Botulinum Toxin by
Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 104: UK Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 105: UK 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 106: UK Current & Future Analysis for Botulinum Toxin by
End-Use - Specialty & Dermatology Clinics, Hospitals & Clinics
and Other End-Uses - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 107: UK Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and Other
End-Uses Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 108: UK 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

SPAIN
Table 109: Spain Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 110: Spain Historic Review for Botulinum Toxin by Product -
Type A and Type B Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 111: Spain 15-Year Perspective for Botulinum Toxin by
Product - Percentage Breakdown of Value Sales for Type A and
Type B for the Years 2012, 2020 & 2027

Table 112: Spain Current & Future Analysis for Botulinum Toxin
by Application - Therapeutics and Aesthetics - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 113: Spain Historic Review for Botulinum Toxin by
Application - Therapeutics and Aesthetics Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 114: Spain 15-Year Perspective for Botulinum Toxin by
Application - Percentage Breakdown of Value Sales for
Therapeutics and Aesthetics for the Years 2012, 2020 & 2027

Table 115: Spain Current & Future Analysis for Botulinum Toxin
by End-Use - Specialty & Dermatology Clinics, Hospitals &
Clinics and Other End-Uses - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 116: Spain Historic Review for Botulinum Toxin by End-Use -
Specialty & Dermatology Clinics, Hospitals & Clinics and
Other End-Uses Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 117: Spain 15-Year Perspective for Botulinum Toxin by
End-Use - Percentage Breakdown of Value Sales for Specialty &
Dermatology Clinics, Hospitals & Clinics and Other End-Uses for
the Years 2012, 2020 & 2027

RUSSIA
Market Overview
Table 118: Russia Current & Future Analysis for Botulinum Toxin
by Product - Type A and Type B - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 119: Russia Historic Review for Botulinum Toxin by

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p0119494/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001